Dr. David R. Spigel, MD
Claim this profileTennessee Oncology
Expert in Non-Small Cell Lung Cancer
Expert in Tumors
29 reported clinical trials
54 drugs studied
About David R. Spigel, MD
Education:
- MD from the University of Texas Southwestern Medical School, 1991.
- Completed Residency in Internal Medicine at Vanderbilt University Medical Center, 1994.
- Fellowship in Hematology/Oncology at Vanderbilt University Medical Center, 1996.
Experience:
- Since 1996, serves as Chief Scientific Officer and Director of the Lung Cancer Research Program at Tennessee Oncology.
Area of expertise
1Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
PD-L1 positive
2Tumors
Global LeaderStage IV
Stage III
MTAP positive
Affiliated Hospitals
Clinical Trials David R. Spigel, MD is currently running
LYL797
for Breast and Lung Cancer
This trial is testing a new treatment called LYL797, which uses modified immune cells to target and kill hard-to-treat breast and lung cancer cells. The study aims to find a safe dose and see how well it works in patients whose cancers have not responded to other treatments.
Recruiting1 award Phase 17 criteria
APL-101
for Lung Cancer
This trial is testing APL-101, a new drug, on patients with specific genetic changes in their cancer. These patients often don't respond to typical treatments. The drug aims to block a protein that helps cancer cells grow and spread.
Recruiting1 award Phase 211 criteria
More about David R. Spigel, MD
Clinical Trial Related3 years of experience running clinical trials · Led 29 trials as a Principal Investigator · 16 Active Clinical TrialsTreatments David R. Spigel, MD has experience with
- Pembrolizumab
- Gemcitabine
- Rituximab
- PD-1 Inhibitor
- Niraparib
- LYL797
Breakdown of trials David R. Spigel, MD has run
Non-Small Cell Lung Cancer
Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David R. Spigel, MD specialize in?
David R. Spigel, MD focuses on Non-Small Cell Lung Cancer and Tumors. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is David R. Spigel, MD currently recruiting for clinical trials?
Yes, David R. Spigel, MD is currently recruiting for 16 clinical trials in Nashville Tennessee. If you're interested in participating, you should apply.
Are there any treatments that David R. Spigel, MD has studied deeply?
Yes, David R. Spigel, MD has studied treatments such as Pembrolizumab, Gemcitabine, Rituximab.
What is the best way to schedule an appointment with David R. Spigel, MD?
Apply for one of the trials that David R. Spigel, MD is conducting.
What is the office address of David R. Spigel, MD?
The office of David R. Spigel, MD is located at: Tennessee Oncology, Nashville, Tennessee 37203 United States. This is the address for their practice at the Tennessee Oncology.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.